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http://www.biomedcentral.com/1471-2407/13/489RESEARCH ARTICLE Open AccessAn explorative analysis of ERCC1-19q13 copy
number aberrations in a chemonaive stage III
colorectal cancer cohort
David Hersi Smith1,2*, Ib Jarle Christensen3, Niels Frank Jensen2, Bo Markussen4, Sven Müller1,
Hans Jørgen Nielsen5,6, Nils Brünner2 and Kirsten Vang Nielsen1,7Abstract
Background: Platinum-based chemotherapy has long been used in the treatment of a variety of cancers and
functions by inducing DNA damage. ERCC1 and ERCC4 are involved in the removal of this damage and have
previously been implicated in resistance to platinum compounds. The aim of the current investigation is to
determine the presence, frequency and prognostic impact of ERCC1 or ERCC4 gene copy number alterations in
colorectal cancer (CRC).
Methods: Fluorescent in situ hybridization probes directed at ERCC1 and ERCC4 with relevant reference probes
were constructed. Probes were tested in a CRC cell line panel and in tumor sections from 152 stage III CRC
chemonaive patients. Relationships between biomarker status and clinical endpoints (overall survival, time to
recurrence, and local recurrence in rectal cancer) were analyzed by survival statistics.
Results: ERCC1-19q13 copy number alterations were observed in a single cell line metaphase (HT29). In patient
material, ERCC1-19q13 copy number gains (ERCC1-19q13/CEN-2≥ 1.5) were detected in 27.0% of specimens,
whereas ERCC1-19q13 deletions (ERCC1-19q13/CEN-2 < 0.8) were only detected in 1.3%. ERCC1-19q13 gain was
significantly associated with longer survival (multivariate analysis, HR: 0.45, 95% CI: 0.20-1.00, p = 0.049) in patients
with colon tumors, but not rectal tumors. No ERCC4 aberrations were detected and scoring was discontinued after
50 patients.
Conclusions: ERCC1-19q13 copy number gains occur frequently in stage III CRC and influences survival in patients
with colon tumors. Future studies will investigate the effect of ERCC1-19q13 aberrations in a platinum-treated
patient population with the aim of developing a predictive biomarker profile for oxaliplatin sensitivity in CRC.
Keywords: ERCC1, ERCC4, XPF, Colorectal cancer, FISH, PrognosisBackground
Oxaliplatin, in combination with 5-Fluorouracil (5-FU,
capecitabine) and additional biological agents, presents one
of two chemotherapy options available for the treatment of
advanced colorectal cancer (CRC). Similar to other platinum
compounds, oxaliplatin exerts its cytotoxic activity by caus-
ing damage to cellular DNA in the form of helix distorting
DNA-platinum adducts, such as intra- and interstrand DNA* Correspondence: dhsmith@dako.com
1R&D, Dako A/S, Produktionsvej 42, Glostrup DK-2600, Denmark
2Section for Molecular Disease Biology, Department of Veterinary Disease
Biology, Faculty of Health and Medical Sciences, University of Copenhagen,
Dyrlægevej 88, Frederiksberg DK-1870, Denmark
Full list of author information is available at the end of the article
© 2013 Smith et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand DNA-protein crosslinks [1,2]. Several DNA repair sys-
tems are involved in the removal of this damage, including
nucleotide excision repair (NER) [3]. NER is initiated by re-
cruitment of several proteins to the site of damage. ERCC1
and ERCC4 (also known as XPF) form a heterodimer with
endonuclease activity, which is recruited at 5′ to the DNA
lesion. Following incision by the complex, another endo-
nuclease (ERCC5, also known as XPG) cleaves at 3′ to the
lesion, allowing removal of the damage nucleotide(s). The
missing fragment is replaced and ligated [4]. Due to a cen-
tral role in NER, as well as interstand crosslink repair [5],
the ERCC1-ERCC4 heterodimer has been widely studied in
relation to platinum resistance.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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between low ERCC1 mRNA expression levels and longer
survival in a stage IV CRC oxaliplatin-treated patient co-
hort [6]. Numerous other studies have attempted to link
ERCC1 protein levels to platinum sensitivity [7-9], however
these studies have relied on the use of a particular mono-
clonal antibody, which has recently been found to bind an
unrelated protein, raising questions towards the validity of
these results [10,11]. Interestingly, studies of gene copy
number alterations involving the ERCC1 locus at 19q13
and ERCC4 locus at 16p13.12 are very limited in number
and have not been performed in CRC [12-14].
Predictive biomarkers can encompass both prognostic
and predictive components, a phenomenon which may
hamper the detection of a beneficial effect from treatment,
unless the prognostic element has been investigated and
mapped [15]. With the aim of identifying a predictive bio-
marker profile for oxaliplatin sensitivity, we have con-
structed two novel FISH probes directed at ERCC1 and
ERCC4 genes, as well as relevant reference probes. These
were subsequently tested these in a CRC cell line meta-
phase panel to identify potential aberrations. Both probe
combinations were subsequently tested in a chemonaive
stage III CRC patient cohort to determine the presence,
frequency and prognostic impact of ERCC1/ERCC4 gene
aberrations. Based on the collected FISH data, scoring
guidelines were established for future use.
Methods
Patients
A total of 154 patients with histologically proven stage
III adenocarcinomas were selected as previously de-
scribed [16,17]. All tumors were resected and patients
did not receive adjuvant chemo- and/or radiotherapy as
this was not part of the standard CRC treatment in
Denmark at the time (1991–1993). Patients were en-
rolled in the RANX05 clinical trial and were randomized
to receive Ranitidine or placebo for up to five years. The
aim of the RANX05 study was to evaluate whether Ra-
nitidine, a histamine type 2 receptor antagonist, could
provide a survival benefit when used as single agent in
the adjuvant setting. Ranitidine had no effect on survival
[18]. The RANX05 trial was conducted in accordance
with the Helsinki II Declaration and was approved by
the Danish National Board of Health (2760-419-1989),
Data Protection Agency (1991-1110-751) and Central
National Ethics Committee (KF 01-2045/91). The ap-
proval included collection of tissue specimens for subse-
quent analysis of biological markers (KF 01-078/93).
Metaphase preparation
Preparation of CRC cell lines metaphases has been reported
previously [16]. Briefly, Colo-205, HCC-2998, HCT-15,
HCT-116, HT29, KM12, and SW620 were obtained fromthe NCI/Development Therapeutics Program, while DLD-
1, LoVo, and LS-174 T were obtained from the American
Tissue Culture Collection. Cell lines were maintained at
37°C, 5% CO2 in relevant growth medium. Once cultures
reached ~ 70% confluence, colcemid (Invitrogen, Carlsbad,
USA) was added to the culture. After 2 h, cells were
harvested and a hypotonic treatment was carried out. Cells
were fixed and dripped onto glass slides.
FISH
Probe design
The ERCC1 gene probe, consisting of bacterial artificial
chromosome (BAC) clones RP11-752G9 (Invitrogen) and
CH17-274E15 (BACPAC Resources, Children’s Hospital
Oakland Research Insitute, Oakland, USA), covers an ap-
proximately 377 kB region containing ERCC1, as well as
several other genes: MARK4, CKM, KLC3, ERCC2,
PPP1R13L, CD3EAP, FOSB, RTN2, PPM1N, VASP, OPA3,
GPR4 and partially EML2. Due to the additional coverage
of genes other than ERCC1, this FISH probe will be re-
ferred to as ERCC1-19q13. Following DNA purification
from culture, BAC clones were labeled with the Texas Red
fluorochrome by nick translation. This gene probe was
combined with a centromere 2-specific probe (Dako,
Glostrup, Denmark), consisting of several FITC-labeled
peptide nucleic acid (PNA) oligomers, which has previ-
ously been found to reflect cellular ploidy levels (described
in [16]). Due to the nature of the repetitive elements in
the centromeric region of chromosome 19, it was not pos-
sible to generate a centromere 19-specific probe. The
ERCC4 gene probe, consisting of BACs CTD-3160 N7
(Invitrogen) and RP11-99H5 (Invitrogen), covers an ap-
proximately 348 kb region, which only contains the
ERCC4 gene and was prepared as described above. This
gene probe was combined with a centromere 16-specific
probe (CEN-16) (Dako). Both gene probes were mixed
their relevant reference probes in the IQFISH Buffer
(Dako) [19].
FISH procedure
The applied FISH reagents were from the Cytology
FISH Accessory Kit (K5499) and the Histology FISH
Accessory Kit (K5799) (Dako). The FISH procedure has
previously been described [16]. Briefly, metaphase spec-
imens were fixed and dehydrated. Once dry, FISH probe
was dripped onto slide and the specimens was dena-
tured and hybridization was performed. Excess probe
was removed by incubation in stringency buffer and
slides were subsequently washed, dehydrated, dried and
mounted. Hybridization to FFPE specimens (thickness:
3 μm) was performed according to the manufacturer’s
recommendations (Dako). Briefly, slides were prepared
by heat pretreatment and pepsin digestion. Slides were
subsequently treated as described above.
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The applied FISH scoring methods have previously been
described [16]. FISH signals were scored according to
TOP2A FISH pharmD×™ guidelines (Code K5333, package
insert, 1st edition, 2008.01.18) at 1000× magnification in
the Texas Red/FITC double filter provided the signals
were, as a minimum, visible at 200× magnification in the
appropriate filter. Although 60 nuclei were scored for each
sample, only nuclei harboring both gene- and reference
signals were included for further analysis.
To determine the presence and mechanism of ERCC1-
19q13 and ERCC4 copy number aberrations in cell lines,
signal locations and numbers were noted for 50 metaphases
for each cell line. The total number of chromosomes for
each cell line has previously been determined [16].
Statistical methods
SAS 9.2 (SAS Institute, Cary, USA) was used to perform
all descriptive and survival statistical analyses. R version
2.15.2 was used in scoring method optimization.
Scoring method optimization
Gene to centromere ratios were calculated by including
the first 10, 20 or 30 nuclei, determining ERCC1-19q13
status and comparing this to the status after inclusion of
all relevant nuclei. Concordance was calculated by use of
Kendall’s tau [tau = (agree-disagree)/(agree + disagree)]. A
borderline interval near the cut-off value (1.5), where add-
itional nuclei must be included (for 10 nuclei, an additional
10 nuclei have to be scored; for 20 nuclei, an additional 20
nuclei have to be scored and so forth) was defined as
greater than or equal to 1.35 (min) and less than 1.65
(max). Concordance and mean number of nuclei scored
were calculated with and without borderline intervals.
Survival analysis
For the survival analysis three clinical endpoints were con-
sidered: overall survival (OS, time to death by any cause),
time to recurrence (TTR, time to any event related to colo-
rectal cancer) and time to local recurrence in rectal cancer
(LR) (described in detail in [17]). Kaplan-Meier estimates
of survival probabilities are presented for the dichotomized
variables. Multivariate Cox regression was done adjusting
for gender, age (per 10 year difference in age) and tumor
localization (colon and rectum). Cox regression analysis
was applied for the analyses. Models were validated by
assessing the proportionality assumption and linearity for
continuous covariates employing Schönfeld and martingale
residuals. ERCC1-19q13 and CEN-2 copy numbers, as well
as the ERCC1-19q13/CEN-2 ratio, were log transformed
(base 2) when analyzed as a continuous variable and there-
fore the hazard ratio (HR) reflected a two-fold difference
for these variables. Results are presented by hazard ratios
hazard ratios with 95% confidence intervals (CI) and p-values. P-values were two-sided and considered significant
at 0.05 for all main effects.
Results
ERCC1-19q13/ERCC4 FISH in cell line panel
To determine the presence and mechanism of ERCC1-
19q13/ERCC4 gene copy number alterations, metaphases
were prepared from a panel of ten CRC cell lines. Meta-
phase preparation was successful for all but one cell line
(LS174T). Hybridization with the ERCC1-19q13/CEN-2
probe revealed the presence of a gene copy number aberra-
tion in HT29. As shown in Figure 1, HT29 appears to har-
bor a copy of chromosome 19 with a single ERCC1-19q13
signal, as well as one harboring 3 signals, producing an
overall ERCC1-19q13/CEN-2 ratio of 1.33. No aberrations
were detected with ERCC4/CEN-16.
Stage III CRC patient material
Samples
A total of 154 FFPE tumor blocks were available for FISH.
As shown in Figure 2, fifty randomly selected samples were
initially assessed with both ERCC1-19q13/CEN-2 and
ERCC4/CEN-16 FISH to determine the presence of gene
aberrations. No aberrations were detected with ERCC4/
CEN-16 and hybridization was discontinued. Following the
detection of aberrations, ERCC1-19q13/CEN-2 hybrid-
ization to FFPE patient specimens was continued and was
successful for 152 (98.7%) of a total of 154 available sam-
ples, specifically 81 colon and 71 rectum specimens. Exam-
ples of FISH analysis can be viewed in Figure 3. Baseline
characteristics including age, gender, tumor location, num-
ber of local recurrences and distant metastases have been
described elsewhere [17].
ERCC1-19q13 FISH
To improve upon assay sensitivity to detect ERCC1-
19q13 copy number alterations, only nuclei harboring
both ERCC1-19q13 and CEN-2 signals were included
for subsequent analysis, which resulted in a median of
53 nuclei scored for each tumor specimen (range: 42–
60). In the patient material, average ERCC1-19q13
counts ranged from 1.08 to 4.37 signals per nucleus
with a median of 2.11, whereas CEN-2 ranged from 1.29
to 2.32 with a median of 1.60. Tumor heterogeneity was
not observed.
The ERCC1-19q13/CEN-2 ratio ranged from 0.65 to
2.47 with a median of 1.28. As shown in Table 1, when
applying relevant ratio cut-off values, tumor specimens
could be separated into three different ERCC1-19q13
statuses. The use of a ratio cut-off of 1.5, reflecting an
additional gene copy in a diploid cell, classified 41
(27.0%) specimens as harboring an ERCC1-19q13 gain.
ERCC1-19q13 gain was more frequently observed in
rectal tumors (24/71 – 33.8%) than colon tumors (17/
Figure 1 Metaphase of HT29. HT29 is a near-triploid CRC cell line, which was found to harbor a 19q isochromosome fused with an additional
(at least partial) duplicated 19q chromosome fragment.
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tion), a ratio of 0.8 was used as a cut-off, which yielded
two samples in this category, both of which were colon
tumors (2/81). The remaining samples were classified
as ‘ERCC1-19q13 Normal’.Figure 2 CONSORT flow diagram describing the selection method ofERCC4 FISH
In the initial 50 FFPE specimens, the ERCC4/CEN-16 ra-
tio ranged from 0.90 to 1.39 with a median of 1.09.
Mean ERCC4 signals per nucleus ranged from 1.37 to
2.35 (median = 1.82), whereas CEN-16 ranged from 1.40samples included in this study.
Figure 3 Representative images of FISH analysis in stage III CRC specimens - taken at 1000x magnification. A: ERCC1-19q13 Normal (ratio
0.99). B: ERCC1-19q13 Deletion (ratio 0.65). C: ERCC1-19q13 Gain (ratio 1.90). D: ERCC4 (ratio 1.21).
Table 2 Univariate survival analysis of the entire cohort
Clinical endpoint Covariate HR 95% CI p-value
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tions, scoring was discontinued.
Association with outcome
The relationship between biomarker status and patient
outcome was explored in both univariate and multivariate
models. In the univariate analysis, only higher ERCC1-
19q13 copy numbers, when analyzed as a continuous vari-
able, were significantly associated with OS (HR: 0.54, 95%
CI: 0.30-0.97, p = 0.04). Higher ERCC1-19q13/CEN-2 ra-
tios and ERCC1-19q13 gain produced a similar trend, al-
though non-significant (see Table 2). It should be noted
that due to the low number of deletions, only the effect of
ERCC1-19q13 gain was investigated. No relationship be-
tween biomarker status, TTR and LR were observed.
Multivariate analysis of age, gender and location has pre-
viously been described [17]. Tumor localization was signifi-
cantly associated with both OS and TTR in the multivariate
analysis where patients with rectal tumors exhibited a
poorer prognosis. Similarly, higher age at time of surgery
was significantly associated with poor prognosis with OSTable 1 ERCC1-19q13 status in 152 CRC samples with
applied cut-offs, observed ratio ranges for each ERCC1-
19q13 status, and the number of specimens in each of
the status groups
ERCC1-19q13
Status
Cut-off values Ratio range Frequency n
(%a)
Deletion < 0.8 0.65-0.69 2 (1.3)
Normal ≥ 0.8 and < 1.5 0.97-1.48 109 (71.7)
Gain ≥ 1.5 1.52-2.47 41 (27.0)
a% denotes percentage of samples relative to total number of samples.and TTR as endpoints. A test of interaction between
the prognostic effect of higher ERCC1-19q13/CEN-2
ratios tumor localization approached significance (p =
0.07 with TTR as endpoint), and therefore the multi-
variate analysis (adjusting for age and gender) was
performed separately for each localization. In this ana-
lysis, higher ERCC1-19q13 copy numbers and ERCC1-
19q13/CEN-2 ratios were significantly associated with
longer survival and TTR in patients with colon tumors,
but not in patients with rectal tumors (see Table 3).
Similarly, ERCC1-19q13 gain was significantly associated
with longer survival (HR: 0.45, 95% CI: 0.20-1.00, p =
0.049) in colon tumors, whereas only a non-significant
trend was observed with TTR as endpoint in the colon
subgroup (HR: 0.42, 95% CI: 0.16-1.07, p = 0.07). Kaplan-
Meier plots for these relationships in the colon subgroup
can be viewed in Figure 4. A test of whether these effectsOS ERCC1-19q13 0.54 0.30-0.97 0.04
ERCC1-19q13/CEN-2 0.62 0.35-1.09 0.10
ERCC1-19q13 gain 0.68 0.44-1.05 0.08
TTR ERCC1-19q13 0.72 0.37-1.41 0.33
ERCC1-19q13/CEN-2 0.58 0.30-1.14 0.11
ERCC1-19q13 gain 0.77 0.48-1.24 0.28
LRa ERCC1-19q13 0.70 0.22-2.27 0.56
ERCC1-19q13/CEN-2 0.99 0.31-3.11 0.98
ERCC1-19q13 gain 0.73 0.33-1.59 0.43
aRectal cancer patients only.
Table 3 Multivariate survival analysis by tumor localization, adjusted for age and gender
Tumor Localization
Colon Rectal
Clinical endpoint Covariate HR 95% CI p-value HR 95% CI p-value
OS ERCC1-19q13 0.32 0.14-0.75 0.01 0.82 0.35-1.95 0.66
ERCC1-19q13/CEN-2 0.37 0.16-0.83 0.02 1.01 0.425-2.25 0.98
ERCC1-19q13 gain 0.45 0.20-1.00 0.049 1.01 0.59-1.75 0.97
TTR ERCC1-19q13 0.34 0.12-1.00 0.0499 0.87 0.36-2.15 0.77
ERCC1-19q13/CEN-2 0.24 0.09-0.70 0.01 0.87 0.36-2.14 0.77
ERCC1-19q13 gain 0.42 0.16-1.07 0.07 1.00 0.56-1.77 0.99
LRa ERCC1-19q13 - - - 0.68 0.20-2.28 0.53
ERCC1-19q13/CEN-2 - - - 0.91 0.28-3.04 0.88
ERCC1-19q13 gain - - - 0.73 0.33-1.60 0.42
aRectal cancer patients only.
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action between the effect of ERCC1-19q13 status and colon
tumor subsite localization (p = 0.84). Higher gene copy
numbers, ratios and ERCC1-19q13 gain were not associated
with LR in rectal cancer patients.Figure 4 Kaplan-Meier plots illustrating patient outcome according to
survival, B: Time to recurrence. Hazard ratios presented are Kaplan-Meier es
confidence intervals.ERCC1-19q13 FISH scoring guidelines
To reduce observer workload, the possibility to scoring
fewer nuclei to determine ERCC1-19q13 status was investi-
gated. ERCC1-19q13 status after scoring 10, 20 and 30 nu-
clei was compared to the status after inclusion of all relevantERCC1-19q13 status in the colon cancer subgroup. A: Overall
timates of survival probabilities with corresponding 95%
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classified samples with moderate concordance (0.71, 0.87
and 0.89, respectively). Following the introduction of a
relevant borderline interval (see material and methods)
concordance was improved substantially (0.86, 0.93 and
0.99, respectively).
Discussion
A single ERCC1-19q13 copy number aberration was ob-
served in the CRC cell line panel. In HT29, a total of four
ERCC1-19q13 signals were detected in this near-triploid
cell line. The finding is somewhat similar to the two differ-
ent karyotypic descriptions available in the NCBI and
NCI’s SKY/M-FISH & CGH database. Both descriptions
list HT29 as harboring a normal copy of chromosome 19
and differ with regards to whether the cell line additionally
harbors either a 19q isochromosome and a derivative fu-
sion chromosome with material from 17q fused at 19qter
[20], or a derivative 19q isochromosome with a duplica-
tion of 19q13.1-13.4 and an unbalanced translocation of
19q12-qter to chromosome 17 [21]. In the current study it
appears that the additional signals from ERCC1-19q13
may be attributed to the formation of a 19q isochromo-
some fused with an additional (at least partial) duplicated
19q chromosome fragment. Taken together, these different
karyotypes indicate that this region appears to be unstable
in HT29. No ERCC4 aberrations were detected.
Analysis of the 152 tumor specimens with ERCC1-19q13/
CEN-2 revealed the presence of both gene deletions and
gene gains. To determine whether the two tumor specimens
with an ‘ERCC1-19q13 Deletion’ status were correctly classi-
fied, mean gene and reference signals were compared to
those previously acquired from unaffected colon mucosa
[16,17]. In the first sample, CEN-2 signal counts were in the
diploid range, whereas gene signals were in the haploid
range, indicative of gene deletion. In the second sample,
ERCC1-19q13 counts were in the diploid range, while those
of CEN-2 were in the triploid range, suggesting that the low
ratio observed for this specimen may be attributed to either
loss of ERCC1-19q13 in a triploid tumor, or chromosome 2
aneusomy. Taken together, these findings suggest that loss
of ERCC1-19q13 occurs infrequently in stage III CRC.
Copy number alterations of the ERCC1 locus are not
widely reported. In ovarian cancer, ERCC1 appears not to
frequently undergo copy number aberrations [12], whereas
it is a more common phenomenon in glioma [13] (note:Table 4 Characteristics of updated scoring guideline
Probe Ratio cut-off Borderline interval
10 nucl
ERCC1-19q13/CEN-2 1.5 none 0.71
1.35-1.65 0.86blotting-based method were applied in both studies). In
non-small cell lung cancer, ERCC1 gene copy number in-
creases were detected by FISH in 25.5% of samples a find-
ing comparable to the 27.0% reported in the present
study, although the FISH probe design and scoring dif-
fered substantially [14]. In this study, Vanhecke and col-
leagues applied an ERCC1 gene probe in combination
with a reference probe directed at 19p13 and followed
EGFR consensus scoring guidelines to classify samples as
either normal, high polysomy or gene amplified [14]. It
should be noted that the use of a reference probe directed
at 19p does not allow the detection of ERCC1 gene copy
increases which occur independently of the rest of 19q, i.e.
gene amplification-driven copy number increases, which
presents a flaw in the design of their probe.
Gain of 19q has previously been reported in colorectal
cancer [22,23], indicating that a reference probe located on
19q would be ideal in differentiating between arm-level
19q gains and those involving a smaller chromosomal frag-
ment, such as an amplicon. In the present study, the use of
an ERCC1-19q13/CEN-2 ratio cut-off of 1.5 in combin-
ation with CEN-2, allows detection of gene copy number
increases of 50% or more relative to tumoral ploidy levels.
Therefore, the assay does not distinguish between gains
due to large chromosomal events, such as chromosome
19 polysomy or 19q isochromosome formation, and those
due to gene amplification, which involve an amplicon. To
determine whether focal amplification occurs in CRC,
GISTIC analysis (Genomic Identification of Significant
Targets in Cancer, [24]) of CRC samples (128 tumor speci-
mens and 33 cell lines) available in the public tumorscape
database (broadinstitute.org/tumorscape) was performed
[25]. The results of this analysis suggest that ERCC1 does
not undergo focal amplification.
As previously mentioned, the ERCC1-19q13 FISH probe
covers several other genes, including ERCC2, FOSB,
PPP1R13L, MARK4 and GPR4. ERCC2 (also known as
XPD) is a 5′→ 3′ helicase involved in unwinding the
double stranded DNA structure around the DNA lesion in
NER prior to ERCC1-ERCC4 incision [4]. Copy number al-
terations of this gene have previously been reported, but
only in the form of infrequent gene loss [12,13]. These find-
ings are in line with the deletion frequency observed in the
present study. It should be noted that FOSB, PPP1R13L
and GPR4 appear to play a role in oncogenesis [26-28], but
do not appear to have been investigated in relation to geneConcordance Mean number of scored nuclei
ei 20 nuclei 30 nuclei 10 nuclei 20 nuclei 30 nuclei
0.87 0.89 10 20 30
0.93 0.99 15.3 26.4 36.5
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undergo gene amplification in glioblastoma cell lines,
resulting in overexpression the MARK4L isoform and in-
creased proliferate capacity [29]. Due to the nature of the
ERCC1-19q13/CEN-2 FISH probe, it is unknown to what
extent other 19q genes are gained in specimens harboring
an ERCC1-19q13 gain. Gain of 19q would result in in-
creased copy number of several well known genes with in-
volvement in cancer, such as BAX [30], CEACAM1 [31,32],
AKT2 [33] and BCL2L12 [34].
Higher ERCC1-19q13 copy numbers were significantly
associated with longer survival in the univariate analysis,
whereas higher ERCC1-19q13/CEN-2 ratios and ERCC1-
19q13 gain produced non-significant trends (see Table 2).
No relationships were observed for TTR and LR as clin-
ical endpoints in the univariate analysis.
In the multivariate analysis, tumor localization was sig-
nificantly associated with OS and TTR, where rectal can-
cers exhibited a poorer prognosis [17]. This finding may be
attributed to the conventional surgical techniques at the
time of specimen collection, which was performed before
the introduction of total mesorectal excision (TME) in
Denmark. TME has since its implementation as a standard
operative procedure significantly improved overall 5-year
survival, with the greatest improvement observed for stage
III patients [35]. Therefore, the clinical outcome of patients
in the rectal cancer subgroup is likely to differ from those
receiving surgery today. It could be of future interest to in-
vestigate the relationship between ERCC1-19q13 gain and
stage III rectal cancer patient prognosis.
Multivariate analysis, performed adjusting for age and
gender, revealed significant relationships between higher
ERCC1-19q13 copy numbers and ERCC1-19q13/CEN-2
ratios and longer survival and TTR in patients with colon
tumors, but not rectal tumors (see Table 3). Similarly,
ERCC1-19q13 gain was significantly associated with longer
survival and exhibited a non-significant trend towards lon-
ger TTR in the colon subgroup. This non-significant find-
ing may be attributed to the low number colon tumor
specimens (17 of 81 specimens) harboring an ERCC1-
19q13 gain. Taken together, these findings suggest that
ERCC1-19q13 copy number increases occur in both colon
and rectal tumors, but are only related to better prognosis
in patients with colon tumors. Colon and rectal tumors are
widely studied as a single entity and a landmark genome-
scale analysis has revealed striking similarities between tu-
mors from either localization, with the exception of tumors
located in the right/ascending colon, which frequently ex-
hibit microsatellite instability (MSI) [22]. While tumors
may exhibit similar genomic profiles, the prognostic im-
pact of a given genetic alteration may differ according to
tumor localization. A study of TP53 mutations, specifically
denaturing mutations, revealed significant prognostic im-
pacts in some tumor localizations (distal colon), but notothers (proximal colon and rectum) [36], a finding with
similarities to that of the present study.
After analysis of the first 50 tumor specimens, ERCC4/
CEN-16 hybridization was terminated due to a lack of ab-
errations, a finding similar to what was observed in the cell
line metaphase panel and also supported by GISTIC ana-
lysis in the tumorscape database. In ovarian cancer, ERCC4
mRNA expression has previously been shown to be tightly
correlated with ERCC1 mRNA expression, indicating that
the mechanisms regulating the expression of these genes
are linked [37]. We therefore suggest that future explora-
tive studies of ERCC1 copy number alterations in other
cancer types also investigate ERCC4 copy numbers, as
these may potentially play a role in ERCC1 expression.
Observer workload can be reduced substantially by re-
quiring fewer nuclei to be scored when determining
ERCC1-19q13 status. Wolff and colleagues [38] suggest a
minimum concordance of 0.95 as a requirement for the
validation of a HER2 assay when compared to a validated
method, a guideline which was adopted for the current
study. Scoring an initial 30 nuclei containing both gene
and centromere signals produced concordance of 0.89,
when compared to scoring all relevant nuclei. By in-
troducing a borderline interval between 1.35 and 1.65,
where an additional 30 nuclei must be scored, con-
cordance increased to 0.99, surpassing the guidelines
set forth by Wolff et al. In the specimens scored in
the present study, these updated guidelines would have re-
duced the amount of nuclei scored by 30.6%. We therefore
suggest that future investigations with ERCC1-19q13/
CEN-2 in CRC score nuclei based upon the aforemen-
tioned updated guidelines.
Conclusions
In conclusion, ERCC1-19q13 gain occurs in a significant
fraction of CRC tumors, whereas deletion of this locus oc-
curs infrequently and was only observed in colon tumors.
In the multivariate analysis, higher ERCC1-19q13 copy
numbers were significantly associated with longer survival
and TTR, but only in patients with colon tumors. Similar
results were observed for the ERCC1-19q13/CEN-2 ratio,
supporting the use of CEN-2 as a marker for chromosomal
ploidy levels. It should be noted that while no relationship
between ERCC1-19q13 status and patient prognosis was
observed in patients with rectal tumors, this does not rule
out the possibility that ERCC1-19q13 status could poten-
tially be linked to oxaliplatin sensitivity in both colon and
rectal tumors. Future plans include testing the ERCC1-
19q13/CEN-2 probe combination in an oxaliplatin-treated
patient cohort to investigate whether ERCC1-19q13
status is related to response to oxaliplatin. Further-
more, the exact mechanisms behind generating higher
ERCC1/ERCC4 expression levels have yet to be fully
elucidated. The downstream effects of ERCC1-19q13
Smith et al. BMC Cancer 2013, 13:489 Page 9 of 10
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current study; however these copy number alterations
may provide the basis for increased ERCC1/ERCC4
protein expression in a gene dosage-dependent man-
ner, a hypothesis which requires testing with validated
ERCC1 and ERCC4 antibodies.
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